NYSE American · ATNMHealthcarePharmaceuticals

Actinium Pharmaceuticals news

$1.14−3.39%

Close Sep 29, 2026 · split-adjusted

Articles · 30 days0English, de-duplicated

Positive0

Neutral0

Negative0

About Actinium Pharmaceuticals

No recent articles focused on Actinium Pharmaceuticals.

Also mentions ATNM

Articles that tag ATNM but are mainly about other companies.

Targeted Alpha Therapy Market Landscape Report 2026-2030: Clinical Trials Insights on 30 Drugs - Size, Regulatory Approvals, Proprietary Technologies, Therapeutic Applications

GlobeNewswire Inc.Apr 21, 4:27 AM ET▲ Positive

Listed as a major company driving targeted alpha therapy R&D with cutting-edge treatment development, indicating active pipeline and market leadership position.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology